Half Year 2026 DocMorris AG Earnings Call Transcript
Key Points
- DocMorris AG (XSWX:DOCM) delivered a 38% direct growth in H1 2026, accelerating to 46% in Q2, with continued momentum into July and August.
- The company's AI-first strategy is on track, with the full rollout of its AI health and shopping assistant, leading to higher conversion rates and customer engagement.
- Rx revenue reached a record EUR86.9 million in Q2 2026, doubling compared to the eRx start in Q2 2024, with strong sequential growth and customer loyalty improvements.
- Digital services, including teleclinic and retail media, grew 71% in H1 and 80% in Q2, contributing to higher margins and profitability.
- The company raised its full-year 2026 guidance, reflecting confidence in achieving EBITDA break-even in 2026 and free cash flow break-even in 2027.
- The company incurred one-off restructuring costs of CHF9.1 million in H1 2026, including CHF7.6 million related to warehouse closure and AI-first strategy layoffs.
- Gross margin remained stable despite a negative impact of approximately 50 basis points from co-payment exemptions, which could pressure profitability if not offset.
- Net debt increased by CHF36 million to CHF174 million, partly due to higher receivables from Rx growth, impacting working capital.
- The company faces uncertainty regarding the sustainability of co-payment coverage strategy, with potential future costs as co-payments rise in 2027.
- OTC growth was modest at 4%, with management intentionally calibrating volumes to focus on higher-margin Rx customers, potentially limiting top-line growth in this segment.
Good morning, ladies and gentlemen, and welcome to DocMorris AG's conference call on the half-year results for 2026. This conference is being recorded. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions following the presentation. If you would like to ask a question, then you could press *9 and pound key on your telephone keypad or use the dial-in function in the webcast and raise your hand. Let me now turn the floor over to your host, Walter Hess.
Yes, thanks a lot.
Welcome, everybody, to our H126 results conference call.
Today with me is Daniel, our CFO, and I'm Otto has the CEO.
The first half of '26 has been a milestone period for DocMorris, marked by accelerated growth and an outstanding operational execution.
Our focus remains on scaling our integrated digital and AI-driven healthcare platform to deliver long-term profitable value.
Today's agenda foresees
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
